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Introduction  
Chronic intestinal pseudo-obstruction (CIPO) is characterized 
by a severe impairment of gastrointestinal (GI) motility leading to 
signs and symptoms indicative of intestinal obstruction in the ab-
sence of any occluding lesion.1 Although rare, CIPO is an extreme-
ly challenging condition that can be diagnosed in adult and pediat-
ric patients. There are many similarities between adult and pediatric 
CIPO, but recently published guidelines suggested that pediatric 
CIPO should be considered as a specific category of CIPO, hence 
the term PIPO (pediatric intestinal pseudo-obstruction).2 
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Pediatric chronic intestinal pseudo-obstruction is a rare disorder characterized by a severe impairment of gastrointestinal motility 
leading to intestinal obstruction symptoms in the absence of mechanical causes. The diagnosis is usually clinical and diagnostic work 
is usually aimed to rule out mechanical obstruction and to identify any underlying diseases. Treatment is challenging and requires 
a multidisciplinary effort. In this manuscript we describe the youngest child successfully treated with the orally administrable, long-
acting, reversible anti-cholinesterase drug, pyridostigmine. Like other drugs belonging to cholinesterase inhibitors, pyridostigmine 
enhances gut motility by increasing acetylcholine availability in the enteric nervous system and neuro-muscular junctions. Based on the 
direct evidence from the reported case, we reviewed the current literature on the use of pyridostigmine in severe pediatric dysmotility 
focusing on intestinal pseudo-obstruction. The overall data emerged from the few published studies suggest that pyridostigmine is 
an effective and usually well tolerated therapeutic options for patients with intestinal pseudo-obstruction. More specifically, the main 
results obtained by pyridostigmine included marked reduction of abdominal distension, reduced need of parenteral nutrition, and 
improvement of oral feeding. The present case and review on pyridostigmine pave the way for eagerly awaited future randomized 
controlled studies testing the efficacy of cholinesterase inhibitors in pediatric severe gut dysmotility.
(J Neurogastroenterol Motil 2019;25:508-514)
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So far, the management of PIPO is aimed to avoid unnecessary 
surgery (ie, cases should carefully assessed prior to a true surgical 
referral is established), recommend supportive measures, such as 
fluid and electrolyte balance, nutritional support (often via parenter-
al nutrition, while enteral is usually not indicated because of severe 
dysmotility), and symptomatic treatments mainly for nausea/vomit-
ing, diarrhea due to underlying small intestine bacterial overgrowth 
(SIBO) and abdominal pain.1,2 In addition, a key therapeutic target 
is given by prokinetic agents, which are expected to improve altered 
motility thereby ameliorating symptoms and signs of PIPO.2 Proki-
netics, eg, metoclopramide, domperidone, erythromycin, cisapride, 
tegaserod, prucalopride, neostigmine, and pyridostigmine, have 
been used both in CIPO and PIPO to improve intestinal motor 
function and to reduce related symptoms; however, their use has 
been limited by variable efficacy and, for some of them, major un-
acceptable side-effects leading to life-threatening consequences.2 
Cholinesterase inhibitors (CIs) exhibiting prokinetic properties with 
efficacy in controlling symptoms related to acute or chronic severe 
gut dysmotility. CIs, including neostigmine and pyridostigmine, 
increase GI motility by preventing the degradation of acetylcholine, 
the main excitatory neurotransmitter in the GI tract, thus increasing 
its concentration in the synaptic cleft.3,4
A recent meta-analysis showed that neostigmine is a safe and 
effective option for patients with acute colonic pseudo-obstruction 
who failed to respond to conservative management.5 In children 
with hematologic malignancies and acute colonic pseudo-obstruc-
tion neostigmine has been successfully used without side effects.6,7 
Pyridostigmine, an orally long-acting reversible CI, has been used 
with success in adult patients with CIPO who failed standard thera-
pies.8 There are very limited data regarding the use and the efficacy 
of pyridostigmine in PIPO patients.9-12
In this manuscript we describe a 2-year old girl with PIPO 
successfully treated with pyridostigmine and review the available lit-
erature on the use of this drug in this severe form of gut dysmotility. 
To our knowledge this is the youngest child with PIPO treated with 
pyridostigmine. The parents of the herein reported child gave their 
consent to all diagnostic procedures and case report publication.
Case Report  
A 2-year and 4-month old girl was referred to the Emergency 
Department of the Santobono-Pausilipon Children’s Hospital, 
Naples, Italy, for persistent vomiting, diarrhea, and hypoglycemia 
associated to lethargy and asthenia. She had a long-term history of 
constipation, food refusal, and poor weight and height gain start-
ing from the beginning of the weaning. On admission, the patient’s 
weight and height were 9.05 kg and 84 cm, respectively. Physical 
examination revealed poor clinical conditions, skin pallor, evident 
signs of dystrophy, and markedly distended and meteoric abdo-
men, with evident superficial venous reticulum. Laboratory tests 
were normal except for an elevated C-reactive protein (15.7 mg/L, 
normal value < 5). During hospitalization, specific virological ex-
aminations disclosed rotavirus and adenovirus infection. Radiologic 
findings showed gaseous distension of bowel loops with evident air-
fluid levels (Fig. 1). A CT-enterography showed massive dilation of 
the entire GI tract, including esophagus and rectum, in the absence 
of mechanical causes (Fig. 2). Esophago-gastro-duodenoscopy and 
colonoscopy (with mucosal biopsies) were normal. Gastrografin en-
ema showed massive colo-rectal dilation. Histopathological exami-
nation of suction rectal biopsies excluded Hirschsprung’s disease. 
Based on clinical and radiological findings a diagnosis of PIPO was 
established. Due to the persistence of abdominal distention, colicky 
abdominal pain and vomiting in the absence of spontaneous bowel 
movements the patient was managed with parenteral nutrition, 
oral metronidazole, and rectal tube placement to facilitate intestinal 
decompression. During parenteral nutrition there was an improve-
ment of abdominal distension and pain in the absence of vomiting, 
whereas bowel movements were absent. She tolerated amino acid 
formula, but all re-feeding attempts with solid foods induced rapid 
symptom recurrence (ie, intestinal subocclusive crisis). After 20 
Figure 1. Upright plain abdominal radiograph showing markedly di-
lated bowel loops with clear-cut air-fluid levels in the reported patient. 
Notably, a massive gastric dilatation (*) with fluid stagnation (arrows) 
is clearly detectable.
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days, the baby had a Candida albicans-central venous catheter-
related sepsis successfully treated with intravenous fluconazole (5 
mg/kg twice a day [bid]) and catheter removal.
In an attempt to improve gut motility, the patient was treated 
with pyridostigmine at a dose of 2 mg/kg bid and gradually in-
creased to 3 mg/kg bid, with drug safety being monitored via heart 
rate and breathing. After 3 days she had a good clinical response 
with disappearance of vomiting, reduction of abdominal distension, 
and occurrence of spontaneous bowel movements. Also, she was 
able to tolerate a normal caloric intake (1000 kcal/day) and after 3 
months there was a weight gain of 1.5 kg.
Discussion  
Both CIPO and PIPO are the most severe clinical phenotypes 
of gut motility disorders with significant morbidity and potentially 
lethal consequences.1,2 Likewise CIPO, also PIPO is a rare disease 
with poorly defined incidence and prevalence in the general popula-
tion. Specifically for PIPO, limited epidemiological data suggested 
an incidence of approximately 1 per 40 000 live births in the United 
States. Half to two-thirds of patients manifest their disease within 
the first month of life and 80% in the first year of age. The remain-
ders are detected sporadically throughout the first 2 decades of life.2 
The diagnosis should be suspected in any child manifesting with 
symptoms of intestinal obstruction without an occluding lesion. 
The clinical manifestations of PIPO depend on the regions of the 
GI tract involved and the dynamics of presentation that is acute, 
intermittent or chronic. Various triggers including infections, gen-
eral anesthesia and emotional stress may precipitate exacerbations 
with subocclusive episodes. Diarrhea due to bacterial overgrowth is 
frequent, and may alternate with constipation or intestinal subocclu-
sive episodes. Abdominal pain, often resulting from even minimal 
amount of eating, may be severe enough to lead to feeding dif-
ficulties resulting in malnutrition.1,2 Dysmotility of the gallbladder 
and cholelithiasis may complicate the clinical picture, increase the 
morbidity, and worsen the prognosis of this condition.1,2 Urinary 
tract involvement occurs in 33% to 92% of cases.2 Megacystis with 
a hypocontractile detrusor is the most frequent pattern of urologi-
cal abnormality. Uretero-hydronephrosis is seen in 56% to 68% 
of cases, although vesico-ureteral reflux occurs in less than 10%.2 
Based on this background, it is clear that PIPO is a challenging 
condition for most physicians. Two main aspects should be pointed 
out about the reported case: (1) the symptoms/signs at the begin-
ning of the weaning, the progressive deterioration of her clinical 
condition, and failure to thrive had been underestimated; and (2) an 
acute episode of viral gastroenteritis, due to a combination of rotavi-
rus and adenovirus infection, was probably the trigger precipitating 
the onset of the disease. Indeed post-acute/post-infectious CIPO 
and PIPO have been previously reported and about 25% of CIPO 
cases has some relationship with a demonstrable infection occur-
ring in the clinical history prior to the onset of enteric dysmotility.2,13 
The recurrent episodes of intestinal sub-occlusion along with the 
results of endoscopic and imaging tests, including plain abdomi-
nal radiographs and a CT-enterography, excluded any mechanical 
obstructions, and showed diffuse GI dilatation, thus leading to the 
diagnosis of PIPO. For the sake of clarity, we would like to point 
out that this patient is still under scrutiny for genetic abnormalities 
affecting the neuro-muscular integrity of the GI tract. The possibil-
ity of underlying enteric neuro-muscular changes may be plausible 
in the reported case, but specific tests, such as intestinal manometry 
Figure 2. Contrast enhanced abdominal 
CT scan performed during the diagnos-
tic work-up in order to rule out possible 
adhesions. (A) Axial and (B) sagittal 
reformatted images illustrate a massive 
dilatation involving the entire gastroin-
testinal tract.
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or small bowel full thickness histopathology were not attempted. 
Also, other tests were negative for major neurological impairment 
or secondary forms of PIPO.
Another challenge of this case was how to manage such a 
young baby showing a severe, potentially life-threatening gut bowel 
dysfunction. Indeed, central vein catheter-related septicemia is a 
frequent and potentially fatal complication in patients with paren-
teral nutrition.14 When septicemia occurs, the catheter should be re-
moved, which is a measure exposing these fragile patients to an in-
creased risk of metabolic abnormalities. In the following paragraphs 
we highlighted the possible beneficial effects of CIs as emerged by 
the direct experience of this case. CIs may represent a possible op-
tion for managing such difficult cases and this knowledge may aid 
pediatricians, and more broadly, physicians dealing with PIPO. 
Management of Pediatric Intestinal Pseudo-
obstruction With Pyridostigmine: Review of 
Current Literatures  
Similarly to CIPO, the pillars of PIPO management are pri-
marily directed to: (1) avoid unnecessary surgery, (2) restore fluid 
and electrolyte balance, (3) maintain an adequate caloric intake 
(via enteral or parenteral nutrition when needed), and (4) provide 
pharmacological support aimed at improving coordinated intestinal 
motility, treat severe symptoms (ie, abdominal pain, disabling nau-
sea, and vomiting), and limit complications such as the occurrence 
of sepsis and SIBO.1,2 The term prokinetics is used to indicate a 
number of pharmacological compounds capable of improving GI 
motility, ranging from dopamine receptor antagonists (eg, domperi-
done and metoclopramide), motilin receptor agonists (erythromycin 
and azithromycin), and 5-hydroxytryptamine 4 receptor agonists 
(such as cisapride, tegaserod, and prucalopride), and CIs (neo-
stigmine and pyridostigmine). Only scant data exist on the effects 
of prokinetics in CIPO and PIPO, but overall, current evidence 
suggests that beneficial effects can be obtained in some patients. 
Because of the severe symptoms patients with intestinal pseudo-
obstruction and marked intestinal dilatation, CIs are emerging as 
a practical therapeutic option hopefully useful for both CIPO and 
PIPO patients. Indeed, the herein case report suggests the interest-
ing possibility that CIs can be safe and effective in the very peculiar 
pediatric setting represented by the very first years of age.
Pharmacological Properties
Reversible CIs are well known drugs, which were mainly used 
in general anesthesia and in the symptomatic treatment of patients 
with myasthenia gravis.15 In the GI tract, the inhibition of choline 
acetyl esterase enzyme increases the availability of acetylcholine at 
the neuro-neuronal synaptic cleft within the enteric nervous system 
as well as at neuromuscular junctions. As a result, acetylcholine, act-
ing via nicotinic (neuro-neuronal site) and muscarinic (neuromus-
cular site) receptors, leads to smooth muscle contractions, which is 
the basic mechanism for enhancing motility.3 CIs include various 
molecules, the best known being neostigmine, pyridostigmine and 
physostigmine. Unlike neostigmine and pyridostigmine, physo-
stigmine crosses the blood brain barrier and its use is substantially 
limited to toxicological applications or anesthesiological settings. 
However, in patients with increased blood-brain barrier permeabil-
ity, pyridostigmine and neostigmine therapy may rarely trigger psy-
chopathological symptoms/signs creating even psychotic pictures.16 
A central cholinergic syndrome caused by the ability of CIs to cross 
the blood-brain barrier, as a result of an inflammatory or concomi-
tant genetic background, may cause these neurological side effects.
Neostigmine and pyridostigmine show similar clearance (0.5-1 
L/hr/kg) and comparable short half-lives (in the range of 30 min-
utes to 90 minutes), but they differ in terms of bioavailability with 
pyridostigmine being about 20-30% vs only 1-2% for neostigmine, 
since the former is usually administered by the oral route, while the 
latter is typically given intravenously. The difference in bioavailabil-
ity is probably responsible for a more rapid effect of neostigmine, 
compared to pyridostigmine in the clinical setting.17,18 Finally, a 
pharmacodynamic parameter that is sometimes used to monitor 
CIs is represented by red blood cell cholinesterase activity, especially 
when CIs are administered in patients with chronic diseases such 
as myasthenia gravis.19-22 For example, a single oral dose of 5 mg 
of pyridostigmine inhibited red blood cell cholinesterase by about 
15%, a result generally considered a safe level of inhibition.23-25
Clinical Evidences
Both neostigmine and pyridostigmine have been shown to be 
able to promote GI motility. Intravenous neostigmine has proven 
efficacy in adult and pediatric acute colonic pseudo-obstruction.5,6 
A recent meta-analysis of 4 studies evaluating 127 patients showed 
that neostigmine (intravenous dose range 2 mg to 5 mg) is a 
safe and effective option for patients with acute colonic pseudo-
obstruction who failed to respond to conservative management.5 In 
children with hematologic malignancies and acute colonic pseudo-
obstruction neostigmine 0.01 mg/kg (maximum 0.5 mg/kg) twice 
daily for a maximum of 5 total doses has been successfully used 
without side effects.7
Pyridostigmine, an oral, long-acting, and reversible CI, has 
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been used with success in both CIPO and PIPO, as indicated by 
at least 5 studies so far published (Table). O’Dea et al8 reported 
7 adult patients with CIPO who failed standard therapies. Five 
of these patients had post-surgical CIPO, 1 had post-pneumonia 
CIPO and 1 had a mitochondrial disorder (mitochondrial encepha-
lopathy, lactic acidosis, and stroke-like episodes syndrome)-related 
CIPO. In these study populations the administration of 10 mg bid 
pyridostigmine, then increased to a maximum of 30 mg bid (in 4 
patients), evoked a good clinical response in all patients consisting 
of a decreased abdominal pain and discomfort with reduction of 
laxative use. None of the 7 patients experienced side effects. Two 
of these patients underwent later surgery (1 total colectomy and 1 
small bowel resection) for recurrent symptoms. Pyridostigmine was 
discontinued in 1 patient after initial response due to recurrence of 
symptoms.
In the pediatric setting, Boybeyi et al9 first reported a positive 
outcome by pyridostigmine in a 3-year old child with a history 
of abdominal distension since the very first days of his life. This 
young patient was admitted at the age of 6 months with vomit-
ing, abdominal distension, and eating difficulties. Imaging stud-
ies revealed microcolon and a megacystis without urinary reflux 
(likely a case of megacystis microcolon intestinal hypoperistalsis 
syndrome). Histopathologic examination of surgical specimens did 
not reveal any neuromuscular abnormalities. The child, treated with 
pyridostigmine at an initial dose of 30 mg/kg/day, reported a good 
clinical response as indicated by discontinuation of nasogastric tube 
decompression and, after few days of treatment, by resuming oral 
feeding associated with oral laxative-evoked bowel movements.9 In 
another study Manini and Colleagues described an 18-year-old 
male with an history of chronic constipation and gastroesophageal 
reflux. At the age of 13 he developed abdominal distension, bilious 
emesis, decrease of food intake, and weight loss. He underwent an 
hemicolectomy for a mid-gut volvulus, but after that he became 
totally dependent on parenteral nutrition with subsequent repeated 
subocclusive episodes. When pyridostigmine 0.25 mg/kg bid was 
administered (and further increased up to 0.3 mg/kg/day over the 
next 2 years) the patient resumed oral feeding (ie, 2-3 small meals 
daily), had minimal abdominal distention and reduced parenteral 
nutrition to about 70% of daily caloric need.10 In the 2018, Choud-
hury et al11 described a case of a 9-year old girl with myotonic dys-
trophy and CIPO successfully treated by pyridostigmine. She had 
a long-term history of constipation and intermittent abdominal dis-
tension treated with many types of laxatives without success. Over 
time (within 6 months), she presented with recurrent symptoms 
characterized by acute abdominal distention, colicky abdominal 
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pain, worsening of constipation, and vomiting. Following exclusion 
of possible mechanical causes of obstruction, a diagnosis of CIPO 
was formulated. The patient was treated with gastric drainage and 
oral pyridostigmine started at a dose of 0.5 mg/kg bid and gradually 
increased to 1 mg/kg bid with accurate monitoring of her heart rate. 
She had a good clinical response in terms of reduced abdominal 
distension and gastric drainage, and managed to tolerate increas-
ing amounts of enteral feeding. After discharge from the hospital, 
the patient maintained normal oral feeding accompanied by weight 
gain over a period of 7 months. Because of another mild episode of 
abdominal distension and vomiting, which resolved spontaneously 
in 48 hours, the dose of pyridostigmine was increased to 1.5 mg/kg 
twice per day. In a 12-month period of close follow-up the patient 
showed a stable body weight and a long minimally symptomatic (or 
virtually asymptomatic) phase.11
Lee et al12 recently described the use of pyridostigmine in 2 
PIPO patients, an 11-year old girl with major small bowel involve-
ment and a 5-year old girl with altered colonic (but no evidence of 
microcolon) function with congenital megacystis. Both patients had 
visceral myopathy with actin gamma-2 gene mutations. After 10 
days of intravenous neostigmine (0.5 mg in 50 mL normal saline) at 
0.5 mg per hour, the treatment was switched to oral pyridostigmine 
at a dose of 180 mg/day (case 1) and 7 mg/kg/day (case 2) without 
side effects, reduced hospital length of stay, and need for parenteral 
nutrition support.12 
Based on these studies, one may conclude that an effective dose 
of pyridostigmine in PIPO should range between 0.25 and 7 mg/
kg/day divided into 2 or 3 doses.9-12 In clinical practice, patients 
with chronic gut dysmotility problems should be treated starting 
with low doses followed by a progressive increase of pyridostig-
mine, whereas in patients with acute gut dysmotility pyridostigmine 
should be started at high doses tapered down to the minimal effec-
tive dose.10 Data on long-term duration therapy are not available; in 
our case we have used pyridostigmine for 6 months with persistent 
beneficial clinical effects.
Pyridostigmine is usually well tolerated and no major side ef-
fects have been described in 13 patients (7 adults and 6 pediatric) 
with CIPO or PIPO described in the literatures. Nonetheless, 
although in other non-GI indications (such as myasthenia gravis), 
pyridostigmine may cause increased salivation, nausea, vomiting, 
and diarrhea. Also abdominal cramps have been reported and are 
thought to be due to powerful intestinal contractions induced by the 
drug, particularly if in the presence of adhesions obstructing the gut 
lumen. Other side effects include muscle weakness, fasciculations 
and cramps, miosis, increased urinary frequency, and increased 
bronchial secretion.15 The risk of side effects increases with the 
increase of the dose. Therefore, pyridostigmine is contraindicated 
in mechanical intestinal or urinary obstruction, bradycardia, and 
particular caution should be used in patients with bronchial asthma.
In conclusion, we herein describe the youngest child with se-
vere gut dysmotility, ie, PIPO, successfully treated with pyridostig-
mine. In line with the available literature, our report suggests that 
pyridostigmine is a safe and effective, orally administrable, and 
therapeutic option also in fragile patients with few years of life suf-
fering from severe gut dysmotility.
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